Literature DB >> 33396524

Correlation of Biomarkers with Endoscopic Score: Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in Patients with Ulcerative Colitis in Remission.

Corina Silvia Pop1,2, Petruta Violeta Filip2, Sorina Laura Diaconu1,2, Clara Matei1,3, Florentina Furtunescu1.   

Abstract

Background: Ulcerative colitis is a disease with an unpredictable evolution, often highlighted endoscopically, that is associated with persistent inflammation affecting the patient's quality of life. An attempt was made to discover surrogate markers to evaluate the endoscopic remission of the disease in order to increase the patient's quality of life and also their adherence to the treatment and monitoring plan. One such marker is fecal calprotectin (FC). Aims: To confirm the correlation between biomarkers and endoscopic disease activity and to define the optimal cut off value to detect clinical and endoscopic remission in a center of Romania.
Methods: This was a prospective study that included 59 patients diagnosed with ulcerative colitis at the Department of Internal Medicine III, University Emergency Hospital of Bucharest. Patients had fecal calprotectin measurements and colonoscopy/rectosigmoidoscopy performed during baseline, 6 and 12 months. For endoscopic activity the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) was used.
Results: During the study, relapses have occurred in 35.6% of patients, the median age was 47 years (21-77). During the study, the FC measurement was significantly increased at 3 months (median, range µg/g; 715, 14-4000) and at 6 months (median, range µg/g; 650, 4.5-3000) (p ≤ 0.05). Another inflammatory biomarker studied was CRP, which showed increased values at 3 months (median, range, mg/dL; 1.86, 0.14-58.9), at 6 months (median, range, mg/dL; 2.36, 0.12-45.8) and at 9 months (median, range, mg/dl; 2, 0.12-25.9) compared to the baseline (p = 0.01). Patients with recurrence of the disease also associated an increase in the values of clinical evaluation scores (SCCAI; p = 0.00001), but also endoscopic (UCEIS; p = 0.0006)
Conclusion: A relapse is associated independently with younger age, the extension of the disease (E2-E3), increased FC level, C reactive protein, hemoglobin concentration, SCCAI index and UCEIS score.

Entities:  

Keywords:  C-reactive protein; endoscopic remission; fecal calprotectin; hemoglobin concentration; ulcerative colitis

Mesh:

Substances:

Year:  2020        PMID: 33396524      PMCID: PMC7823820          DOI: 10.3390/medicina57010031

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  19 in total

1.  Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.

Authors:  F Costa; M G Mumolo; L Ceccarelli; M Bellini; M R Romano; C Sterpi; A Ricchiuti; S Marchi; M Bottai
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

2.  Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test.

Authors:  Shiho Takashima; Jun Kato; Sakiko Hiraoka; Asuka Nakarai; Daisuke Takei; Toshihiro Inokuchi; Yuusaku Sugihara; Masahiro Takahara; Keita Harada; Hiroyuki Okada; Takehiro Tanaka; Kazuhide Yamamoto
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

3.  Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.

Authors:  Wing Yan Mak; Anthony Buisson; Michael J Andersen; Donald Lei; Joel Pekow; Russell D Cohen; Stacy A Kahn; Bruno Pereira; David T Rubin
Journal:  Dig Dis Sci       Date:  2018-02-22       Impact factor: 3.199

4.  Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis.

Authors:  Klaus Theede; Susanne Holck; Per Ibsen; Steen Ladelund; Inge Nordgaard-Lassen; Anette Mertz Nielsen
Journal:  Clin Gastroenterol Hepatol       Date:  2015-06-04       Impact factor: 11.382

5.  Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response.

Authors:  D Turner; S T Leach; D Mack; K Uusoue; R McLernon; J Hyams; N Leleiko; T D Walters; W Crandall; J Markowitz; A R Otley; A M Griffiths; A S Day
Journal:  Gut       Date:  2010-09       Impact factor: 23.059

Review 6.  Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.

Authors:  N Waugh; E Cummins; P Royle; N-B Kandala; D Shyangdan; R Arasaradnam; C Clar; R Johnston
Journal:  Health Technol Assess       Date:  2013-11       Impact factor: 4.014

7.  A simple clinical colitis activity index.

Authors:  R S Walmsley; R C Ayres; R E Pounder; R N Allan
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

8.  The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score.

Authors:  Kentaro Ikeya; Hiroyuki Hanai; Ken Sugimoto; Satoshi Osawa; Shinsuke Kawasaki; Takayuki Iida; Yasuhiko Maruyama; Fumitoshi Watanabe
Journal:  J Crohns Colitis       Date:  2015-11-17       Impact factor: 9.071

9.  Comparing disease activity indices in ulcerative colitis.

Authors:  A J Walsh; A Ghosh; A O Brain; O Buchel; D Burger; S Thomas; L White; G S Collins; S Keshav; S P L Travis
Journal:  J Crohns Colitis       Date:  2013-10-10       Impact factor: 9.071

10.  Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis.

Authors:  Tingbin Xie; Tenghui Zhang; Chao Ding; Xujie Dai; Yi Li; Zhen Guo; Yao Wei; Jianfeng Gong; Weiming Zhu; Jieshou Li
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-04-26
View more
  1 in total

Review 1.  How to assess endoscopic disease activity in ulcerative colitis in 2022.

Authors:  Mirko Di Ruscio; Marco Cedola; Manuela Mangone; Stefano Brighi
Journal:  Ann Gastroenterol       Date:  2022-07-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.